Literature DB >> 23740132

Should be NICE have a Spanish NICE?

J Feliu, E Espinosa.   

Abstract

Mesh：

Year:  2013        PMID： 23740132     DOI： 10.1007/s12094-013-1051-z

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  11 in total

Review 1.  Development of WHO guidelines on generalized cost-effectiveness analysis.

Authors:  C J Murray; D B Evans; A Acharya; R M Baltussen
Journal:  Health Econ       Date:  2000-04       Impact factor: 3.046

2.  The price tag on progress--chemotherapy for colorectal cancer.

Authors:  Deborah Schrag
Journal:  N Engl J Med       Date:  2004-07-22       Impact factor: 91.245

3.  Health care costs: how do we decide value? When do we decide? How do we particularize the decisions?

Authors:  Richard L Theriault
Journal:  Oncologist       Date:  2012-02-02

4.  When are "positive" clinical trials in oncology truly positive?

Authors:  Alberto Ocana; Ian F Tannock
Journal:  J Natl Cancer Inst       Date:  2010-12-03       Impact factor: 13.506

5.  Delivering affordable cancer care in high-income countries.

Authors:  Richard Sullivan; Jeffrey Peppercorn; Karol Sikora; John Zalcberg; Neal J Meropol; Eitan Amir; David Khayat; Peter Boyle; Philippe Autier; Ian F Tannock; Tito Fojo; Jim Siderov; Steve Williamson; Silvia Camporesi; J Gordon McVie; Arnie D Purushotham; Peter Naredi; Alexander Eggermont; Murray F Brennan; Michael L Steinberg; Mark De Ridder; Susan A McCloskey; Dirk Verellen; Terence Roberts; Guy Storme; Rodney J Hicks; Peter J Ell; Bradford R Hirsch; David P Carbone; Kevin A Schulman; Paul Catchpole; David Taylor; Jan Geissler; Nancy G Brinker; David Meltzer; David Kerr; Matti Aapro
Journal:  Lancet Oncol       Date:  2011-09       Impact factor: 41.316

6.  A global comparison regarding patient access to cancer drugs.

Authors:  B Jönsson; N Wilking
Journal:  Ann Oncol       Date:  2007-04       Impact factor: 32.976

7.  How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.

Authors:  Tito Fojo; Christine Grady
Journal:  J Natl Cancer Inst       Date:  2009-06-29       Impact factor: 13.506

8.  What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?

Authors:  R Scott Braithwaite; David O Meltzer; Joseph T King; Douglas Leslie; Mark S Roberts
Journal:  Med Care       Date:  2008-04       Impact factor: 2.983

9.  Chemotherapy at the end of life: up until when?

Authors:  Jaime Sanz Ortiz
Journal:  Clin Transl Oncol       Date:  2012-07-07       Impact factor: 3.405

10.  Cancer's next frontier: addressing high and increasing costs.

Authors:  Elena B Elkin; Peter B Bach
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272
View more
  1 in total

1.  The Off-Label Use of Antineoplastics in Oncology Is Limited But Has Notable Scientific Support in a University Hospital Setting.

Authors:  Marta Herrero Fernandez; Raquel Molina Villaverde; Monica Arroyo Yustos; Fatima Navarro Expósito; Jose Luis Lopez Gonzalez; Maria Rosario Luque Infantes; Melchor Alvarez-Mon Soto
Journal:  Front Pharmacol       Date:  2019-10-23       Impact factor: 5.810
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.